NCT00470327

Brief Summary

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for all trials

Timeline
54mo left

Started Sep 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Sep 2005Dec 2030

Study Start

First participant enrolled

September 1, 2005

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

May 3, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 7, 2007

Completed
23.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

June 9, 2026

Status Verified

June 1, 2026

Enrollment Period

25.3 years

First QC Date

May 3, 2007

Last Update Submit

June 5, 2026

Conditions

Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisSarcoidosisConnective Tissue Disorder

Keywords

Interstitial lung diseasesidiopathic pulmonary fibrosisSarcoidosismRNA and cytokine expression

Outcome Measures

Primary Outcomes (1)

  • Natural history of course of disease in patients with Interstitial lung disease (ILD)

    We assess mortality roughly yearly but duration is unlimited

    Yearly

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects cared for in the ILD (Interstitial Lung Disease)clinic

You may qualify if:

  • Interstitial lung disease

You may not qualify if:

  • Does not have Interstitial lung disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Chicago

Chicago, Illinois, 60637, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisSarcoidosisConnective Tissue Diseases

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesPulmonary FibrosisLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesHypersensitivity, DelayedHypersensitivityImmune System DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mary E Strek, MD

    University of Chicago

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Vanita Patel, MPH

CONTACT

773-702-1012

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2007

First Posted

May 7, 2007

Study Start

September 1, 2005

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2030

Last Updated

June 9, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will share

We will share coded data with no PHI

Locations

US(1)